News

Delivering timely, appropriate antimicrobial therapy is an international care standard to help provide the best outcomes for patients with sepsis.1 The optimum duration of antibiotic treatment for sepsis is uncertain, with decisions to stop therapy guided by clinical progress and serum inflammatory biomarkers such as serum C-reactive protein (CRP) and procalcitonin (PCT).2 Optimizing antibiotics duration helps reduce overtreatment, limits unwanted effects, and preserves antibiotic effectiveness by minimizing resistance.3 Biomarker-guided discontinuation, especially with PCT, has shown safe reductions in antibiotic duration.4 However, the body of clinical trial evidence has been judged to be low quality1,5,6 leading to a weak recommendation for routine sepsis care adoption of PCT-guided antibiotic discontinuation1 and with no consensus guidance for CRP.1